Today on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt, a highly experienced neuropsychopharmacologist, the chair of the scientific advisory board for Compass Pathways (NASDAQ: CMPS), and a director of Psyched Wellness (CSE: PSYC). David joins us this morning to discuss psychedelics and the science behind it, clinical research, and his take on Amanita Muscaria.
Psyched Wellness is focused on the distribution of mushroom derived products and related consumer packaged goods. The company is currently in the process of developing a product line focused on Amanita Muscaria-derived water based extracts, teas and capsules focused on rpomoting stress relief, relaxation and assistance with restful sleeping.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
The post David Nutt: Amanita Muscaria Due For More Research – The Daily Dive appeared first on the deep dive.